Kelton J G, Huang A T, Mold N, Logue G, Rosse W F
N Engl J Med. 1979 Sep 20;301(12):621-4. doi: 10.1056/NEJM197909203011201.
The confirmation of drug-induced marrow aplasia is difficult since rechallenging the patient can lead to serious morbidity. We used marrow-culture technics to challenge in vitro the bone marrow of a patient with marrow aplasia after ingestion of quinidine. There was no clinical or laboratory evidence of quinidine-mediated destruction of erythrocytes, leukocytes or platelets. By contrast, use of quinidine in combination with the patient's serum substantially inhibited in vitro growth of allogeneic marrow granulocytic and erythroid series. Furthermore, use of quinidine in combination with acute-phase serum (but not acute-phase serum alone or quinidine in combination with recovery-phase serum) inhibited growth of the patient's marrow. This observation suggests that both a transient serum factor and quinidine were responsible for the marrow aplasia. These technics could be applied with minimal risk to similar patients and would permit in vitro rechallenge with the suspected drug.
药物性骨髓再生障碍的确诊很困难,因为再次给患者用药可能会导致严重的发病情况。我们采用骨髓培养技术,在体外对一名摄入奎尼丁后发生骨髓再生障碍患者的骨髓进行激发试验。没有临床或实验室证据表明奎尼丁介导了红细胞、白细胞或血小板的破坏。相比之下,将奎尼丁与患者血清联合使用,可显著抑制体外同种异体骨髓粒细胞系和红细胞系的生长。此外,将奎尼丁与急性期血清联合使用(而非单独使用急性期血清或奎尼丁与恢复期血清联合使用)可抑制患者骨髓的生长。这一观察结果表明,短暂的血清因子和奎尼丁均与骨髓再生障碍有关。这些技术应用于类似患者时风险极小,并且可以对疑似药物进行体外再激发试验。